Fulgent Genetics, Inc. (FLGT) Q3 2026 earnings results
Fulgent Genetics, Inc. (FLGT) reported Q3 2026 results on Nov 5, 2026, 4:08:37 PM ET: adjusted EPS -$0.09 vs. -$0.65 expected (beat by 86.2%); revenue $90.41M vs. $86.30M expected (beat by 4.8%). Outlook: Maintains annual revenue guidance of $330.0-$340.0 million.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (adjusted, diluted) | -$0.09 | -$0.65 | Beat by 86.2% |
| Revenue | $90.41M | $86.30M | Beat by 4.8% |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Nov 5, 2026, 4:08:37 PM ET. Nexqual published them 2 min 33 s after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 7.5% from $84.07M.
Stock reaction
The results came out after the market closed. FLGT closed at $23.74 on November 6, 2026, up 27.2% from its $18.66 close on November 5, 2026 before the results. Latest: $26.75 as of 11:40 AM ET, +43.4% since the pre-release close.
Questions and answers
Did Fulgent Genetics, Inc. beat earnings expectations?
Yes. Fulgent Genetics, Inc. reported adjusted EPS of -$0.09 against an average analyst estimate of -$0.65 (beat by 86.2%), and revenue of $90.41M against $86.30M expected (beat by 4.8%).
What were Fulgent Genetics, Inc.'s Q3 2026 earnings and revenue?
adjusted diluted EPS of -$0.09 and revenue of $90.41M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 7.5% from $84.07M.
When did Fulgent Genetics, Inc. report Q3 2026 earnings?
Nov 5, 2026, 4:08:37 PM ET, in an SEC 8-K filing (Item 2.02).
How did FLGT stock react to the earnings?
The results came out after the market closed. FLGT closed at $23.74 on November 6, 2026, up 27.2% from its $18.66 close on November 5, 2026 before the results. Latest: $26.75 as of 11:40 AM ET, +43.4% since the pre-release close.
What did Fulgent Genetics, Inc. say about its outlook?
Maintains annual revenue guidance of $330.0-$340.0 million.
More on FLGT
FLGT stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings November 5, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built November 10, 2026 at 16:40 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 10, 2026 at 16:40 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt